Malignant pleural effusion and algorithm management.
| Title | Malignant pleural effusion and algorithm management. |
| Publication Type | Journal Article |
| Year of Publication | 2013 |
| Authors | Zarogoulidis, K., Zarogoulidis P., Darwiche K., Tsakiridis K., Machairiotis N., Kougioumtzi I., Courcoutsakis N., Terzi E., Zaric B., Huang H., Freitag L., & Spyratos D. |
| Journal | J Thorac Dis |
| Volume | 5 Suppl 4 |
| Pagination | S413-9 |
| Date Published | 2013 Sep |
| ISSN | 2072-1439 |
| Abstract | Involvement of the pleura in lung cancer is a common manifestation accompanying with reduced life expectancy. Symptoms relief and improvement of the quality of life are the primary goals of the management of malignant pleural effusion (MPE). Histological confirmation is essential for optimal patient management. Lung cancer patients, with life expectancy more than 3 months, resistant to chemotherapy should be treated with thoracentesis, intercoastal tube drainage and installation of a sclerosant agent or pleurodesis through thoracospopic procedures or placement of an indwelling pleura catheter. Talc pleurodesis (sterile asbestos-free graded, particle size >15 μm), as "poudrage" or "slurry" still remains the treatment of choice in patients with MPE resistant to chemotherapy. |
| DOI | 10.3978/j.issn.2072-1439.2013.09.04 |
| Alternate Journal | J Thorac Dis |
| PubMed ID | 24102015 |
| PubMed Central ID | PMC3791493 |
